Innoviva Inc
INVA
Company Profile
Business description
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Contact
1350 Old Bayshore Highway
Suite 400
BurlingameCA94010
USAT: +1 650 238-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
112
Stocks News & Analysis
stocks
2 cheap miners after our commodity price update
These two companies are trading at a meaningful discount to our fair value.
stocks
What we think of the 3 big winners of the ASX 100
Exploring the ASX companies who dominated the market this year
stocks
Chart of the week: Where do our analysts see value?
This week's chart of the week looks at the under and overvalued sectors in the Australian market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,558.60 | 64.60 | 0.76% |
| CAC 40 | 7,357.08 | 52.49 | -0.71% |
| DAX 40 | 20,313.81 | 92.11 | -0.45% |
| Dow JONES (US) | 43,717.48 | 110.58 | -0.25% |
| FTSE 100 | 8,262.05 | 38.28 | -0.46% |
| HKSE | 19,711.07 | 84.42 | -0.43% |
| NASDAQ | 20,173.89 | 247.17 | 1.24% |
| Nikkei 225 | 39,364.68 | 92.81 | -0.24% |
| NZX 50 Index | 12,914.30 | 116.97 | 0.91% |
| S&P 500 | 6,074.08 | 22.99 | 0.38% |
| S&P/ASX 200 | 8,314.00 | 64.50 | 0.78% |
| SSE Composite Index | 3,367.11 | 19.22 | -0.57% |